Results 71 to 74 of about 113,471 (74)

QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

British Journal of Cancer
Guangdong Qiao
exaly  

AMPK activator 991 specifically activates SnRK1 and thereby affects seed germination in rice

Journal of Experimental Botany
Jiaqi BAi, Xuemei Xu, Chengqiang Ding
exaly  

QL1701 (a proposed trastuzumab biosimilar) versus reference trastuzumab plus docetaxel as first-line therapy for HER2-positive metastatic breast cancer: a multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial

ESMO Open
exaly  

QL1604 combined with bevacizumab as an innovative first-line treatment for HCC patient with extensive metastasis who showed remarkable effect: a case report

Frontiers in Pharmacology
exaly